Home › NDC Lookup › RxCUI directory › RxCUI 2604622

10 ML risankizumab-rzaa 60 MG/ML Injection [Skyrizi] — RxCUI 2604622

Name: 10 ML risankizumab-rzaa 60 MG/ML Injection [Skyrizi] (RxCUI 2604622)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2604622 Semantic branded drug · SBD ● Current RxNorm concept 10 FDA products 16 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2604622

Official name10 ML risankizumab-rzaa 60 MG/ML Injection [Skyrizi]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known as10 ML Skyrizi 60 MG/ML Injection; Skyrizi 600 MG in 10 ML Injection; Skyrizi 600 MG per 10 ML Injection

FDA products mapped10

Package NDCs mapped16

Reported Medicaid activity (SDUD)82,904 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Risankizumab-rzaa Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Skyrizi is approved for four conditions: moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely...
That depends on what you're treating. For psoriasis or psoriatic arthritis, you get a subcutaneous (under-the-skin) injection at weeks 0 and 4, and then roughly every 12 weeks afte...
How often do I need to take Skyrizi, and do I have to go to a clinic every time?
The most common ones are upper respiratory infections (like colds or sinus infections), headache, fatigue, and reactions at the injection site like redness or soreness. Fungal skin...

📖 Read our full Risankizumab-rzaa Injection guide →

🕸️ Concept Web — How 10 ML risankizumab-rzaa 60 MG/ML Injection [Skyr... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 10 ML risankizumab-rzaa 60 MG/ML Injection [Skyrizi] RxCUI 2604622 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Risankizumab 2166040 IN
- Risankizumab-rzaa 2166132 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Skyrizi 2166138 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Risankizumab Injection 2604617 SCDF
- Risankizumab-rzaa Injection 2647392 SCDFP
- Risankizumab Injectable Product 2166134 SCDG
- Risankizumab-rzaa Injectable Product 2662921 SCDGP
- Risankizumab Injection [Skyrizi] 2604621 SBDF
- Risankizumab-rzaa Injection [Skyrizi] 2655704 SBDFP
- Skyrizi Injectable Product 2166141 SBDG
- Injection 1649574 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 10 ML risankizumab-rzaa 60 MG/ML Injection 2604618 SCD
- Risankizumab-rzaa 60 MG/ML 2604616 SCDC
- Risankizumab-rzaa 60 MG/ML [Skyrizi] 2604620 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

10 ML risankizumab-rzaa 60 MG/ML Injection SCD · 2604618
Risankizumab-rzaa 60 MG/ML SCDC · 2604616
Risankizumab Injection SCDF · 2604617
Risankizumab-rzaa Injection SCDFP · 2647392
Risankizumab Injectable Product SCDG · 2166134
Risankizumab-rzaa Injectable Product SCDGP · 2662921

Brand-Name Concepts

Risankizumab-rzaa 60 MG/ML [Skyrizi] SBDC · 2604620
Risankizumab Injection [Skyrizi] SBDF · 2604621
Risankizumab-rzaa Injection [Skyrizi] SBDFP · 2655704
Skyrizi Injectable Product SBDG · 2166141
Skyrizi BN · 2166138

📦 FDA Products & Package NDCs

10 products · 16 package NDCs

16 package NDCs map to RxCUI 2604622 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00074-1050-01	1 SYRINGE in 1 CARTON (0074-1050-01) / 1 mL in 1 SYRINGE	Skyrizi	AbbVie Inc.	2021-04-26
00074-1050-70	1 SYRINGE in 1 CARTON (0074-1050-70) / 1 mL in 1 SYRINGE	Skyrizi	AbbVie Inc.	2021-04-26
00074-1065-01	1 KIT in 1 CARTON (0074-1065-01) * 1.2 mL in 1 CARTRIDGE (...	Skyrizi	AbbVie Inc.	2022-09-23
00074-1065-02	1 KIT in 1 CARTON (0074-1065-02) * 1.2 mL in 1 CARTRIDGE (...	Skyrizi	AbbVie Inc.	2022-09-23
00074-1070-01	1 KIT in 1 CARTON (0074-1070-01) * 2.4 mL in 1 CARTRIDGE (...	Skyrizi	AbbVie Inc.	2022-06-16
00074-1070-02	1 KIT in 1 CARTON (0074-1070-02) * 2.4 mL in 1 CARTRIDGE (...	Skyrizi	AbbVie Inc.	2022-06-16
00074-2100-01	1 SYRINGE in 1 CARTON (0074-2100-01) / 1 mL in 1 SYRINGE	Skyrizi	AbbVie Inc.	2021-04-26
00074-2100-70	1 SYRINGE in 1 CARTON (0074-2100-70) / 1 mL in 1 SYRINGE	Skyrizi	AbbVie Inc.	2021-04-26
00074-4059-01	1 SYRINGE, GLASS in 1 CARTON (0074-4059-01) / .37 mL in 1 S...	Skyrizi	AbbVie Inc.	2026-06-12
00074-4059-71	1 SYRINGE, GLASS in 1 CARTON (0074-4059-71) / .37 mL in 1 S...	Skyrizi	AbbVie Inc.	2026-06-12
00074-5015-01	1 VIAL, SINGLE-DOSE in 1 CARTON (0074-5015-01) / 10 mL in 1...	Skyrizi	AbbVie Inc.	2022-06-16
00074-5015-02	1 VIAL, SINGLE-DOSE in 1 CARTON (0074-5015-02) / 10 mL in 1...	Skyrizi	AbbVie Inc.	2022-06-16
00074-7040-02	2 CARTON in 1 CARTON (0074-7040-02) / 1 KIT in 1 CARTON *...	Skyrizi	AbbVie Inc.	2024-03-04
00074-7042-04	4 CARTON in 1 CARTON (0074-7042-04) / 1 KIT in 1 CARTON *...	Skyrizi	AbbVie Inc.	2024-03-04
00074-8300-01	1 SYRINGE in 1 CARTON (0074-8300-01) / 1.2 mL in 1 SYRINGE	Skyrizi	AbbVie Inc.	2025-09-03
00074-8350-01	2 SYRINGE in 1 CARTON (0074-8350-01) / 1.2 mL in 1 SYRINGE	Skyrizi	AbbVie Inc.	2025-09-03

Observed labelers: AbbVie Inc. (16) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J2327	Inj risankizumab-rzaa 1 mg	1	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.